市場調査レポート

商品コード

1365783

糖尿病性腎症市場：薬剤クラス別、タイプ別、流通チャネル別：世界の機会分析と産業予測、2022～2031年

Diabetic nephropathy Market By Drugs Class, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

出版日: 2023年08月01日 | 発行: Allied Market Research

| ページ情報: 英文 266 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

糖尿病性腎症市場は、2021年には19億米ドルと評価され、2022年から2031年にかけてCAGR 6%で成長し、2031年には33億米ドルに達すると予測されています。

糖尿病性腎症は、体内の糖濃度が高い状態が長期間続く代謝疾患です。糖尿病には1型と2型があります。糖尿病性腎症は、糖尿病が腎臓に影響を及ぼし、慢性腎臓病や腎臓障害を引き起こす病状です。糖尿病性腎症は、糖尿病患者の死亡率や罹患率の点で最も重要な合併症の一つです。腎症は、老廃物や余分な水分を体外に排出する腎臓の機能に影響を及ぼします。糖尿病性腎症を予防したり遅らせたりする最善の方法は、健康的なライフスタイルを維持し、糖尿病と高血圧を適切に管理することです。腎臓病は、末期腎不全とも呼ばれる腎不全に進行することがあります。腎不全は生命を脅かす状態です。この段階になると、治療の選択肢は透析か腎移植になります。

糖尿病性腎症は通常、糖尿病管理の一環である定期検査で診断されます。糖尿病性腎症の診断に使用されるルーチン検査には、尿中アルブミン検査、アルブミン／クレアチニン比、糸球体濾過量（GFR）、および画像検査（CTスキャン、MRI）、腎生検などの特殊検査があります。

糖尿病性腎症の治療は患者さんにとって非常に必要です。糖尿病性腎症の治療の第一歩は、糖尿病と高血圧の治療とコントロールです。これには、食事療法、生活習慣の改善、運動療法、処方薬、血圧コントロール薬、血糖コントロール薬、G蛋白結合受容体（GPCR）薬、抗酸化炎症調節薬などが含まれます。さらに、進行した糖尿病性腎臓病に対しては、腎臓透析、移植、対症療法も行われます。糖尿病性腎症市場は急速に成長しています。糖尿病性腎症市場の成長を促進する主な要因には、糖尿病を患う老年人口の増加、糖尿病人口の増加、様々な腎疾患の発生率の上昇などがあります。例えば、Journal of Nutrition and Metabolism誌によると、エチオピア北西部のゴンダール大学総合専門病院での調査では、糖尿病性腎症の罹患率は患者1万人当たり14例（95％信頼区間10.8～17.7）でした。また、63例（13.6％）の糖尿病（DM）患者が糖尿病性腎症を発症しました。冠動脈性心疾患や貧血を有する2型糖尿病患者は、糖尿病性腎症を発症する危険性が高かったです。したがって、このような要因が市場の成長を後押ししています。

例えば、National Diabetes Statistics Latest Reportによると、2017年から2020年にかけて、米国では3,730万人が糖尿病を患っており（米国人口の11.3％）、そのうち成人2,850万人を含む2,870万人が診断され、850万人（成人の23.0％）が未診断です。

さらに、糖尿病と慢性腎臓病の急増は糖尿病性腎症の増加につながり、さらに抗糖尿病性腎症薬を必要とするため、抗糖尿病性腎症薬の採用を促進しています。アンジオテンシン変換酵素阻害剤は、糖尿病性腎症治療薬の中でも人気が高いです。2型糖尿病は、顧客の注目を集める最も動向のある糖尿病性腎症であり、糖尿病性腎症市場の成長を促進しています。さらに、技術の進歩、様々な製品の発売、買収、提携、契約などの主要企業間の戦略が糖尿病性腎症市場を牽引しています。例えば、AstraZeneca Plc.は、激しい競争を維持し、製品ポートフォリオを改善するための主要な開発戦略として、フォルキシガの承認を日本と欧州で取得しました。

しかし、不利な償還や合併症の発生により、市場成長はより厳しい規制基準や長い医薬品承認期間によって制限されています。また、糖尿病性腎症に対する包括的な治療法がないため、糖尿病性腎症の市場成長も抑制されています。

さらに、糖尿病や肥満の有病率の上昇、創薬・薬剤開発への研究開発投資の増加、糖尿病や腎臓関連疾患に対する意識の高まりから、医療事業の成長が予測されます。このため、主要企業は予測期間中に同市場へ投資する有益な機会を得られると予想されます。

糖尿病性腎症市場は薬剤クラス別、タイプ別、流通チャネル別、地域別に区分されます。薬剤クラス別では、アンジオテンシン変換酵素阻害薬、アンジオテンシン受容体拮抗薬、カルシウム拮抗薬、利尿薬、レニン阻害薬、その他に分類されます。タイプ別では、市場は1型糖尿病と2型糖尿病に分別されます。流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア＆小売薬局に細分化されます。地域別では、市場は北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋）、アジア太平洋（ブラジル、中国、アラビア、オーストラリア、インド、韓国、その他の南米地域）で分析されます。

本レポートにプロファイルされている主要企業は、Abbott Laboratories、AbbVie Inc.、AstraZeneca Plc、Bayer Ag、Eli Lilly and Company、Merck &Co, Inc.、Novartis Ag、Pfizer Inc.、Reata Pharmaceuticals, Inc.、Sanofiです。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 糖尿病を患う高齢者人口の急増、慢性腎臓病、肥満、高血圧の有病率の上昇
  - 糖尿病性腎症に関する意識の高まりと診断検査の増加
- 抑制要因
  - 厳格な規制規則と長い医薬品承認期間
- 機会
  - 糖尿病性腎症に対する併用療法の増加
  - 創薬および開発における研究開発投資の増加
COVID-19市場への影響分析

第4章糖尿病性腎症市場：薬剤クラス別

概要
アンジオテンシン変換酵素阻害薬
アンジオテンシン受容体遮断薬
カルシウム拮抗薬
利尿薬
レニン阻害薬
その他

第5章糖尿病性腎症市場：タイプ別

概要
1型糖尿病
2型糖尿病

第6章糖尿病性腎症市場：流通チャネル別

概要
病院薬局
オンラインプロバイダー
ドラッグストア＆小売薬局

第7章糖尿病性腎症市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10企業の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2021年

第9章企業プロファイル

AbbVie Inc.
Abbott Laboratories
Bayer AG
Eli Lilly and Company
Merck & Co
Astrazenica Plc
Novartis AG
Pfizer Inc.
Reata Pharmaceuticals
Sanofi

図表

LIST OF TABLES

TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)
TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)
TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. ABBVIE INC.: KEY EXECUTIVES
TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 97. BAYER AG: KEY EXECUTIVES
TABLE 98. BAYER AG: COMPANY SNAPSHOT
TABLE 99. BAYER AG: PRODUCT SEGMENTS
TABLE 100. BAYER AG: PRODUCT PORTFOLIO
TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 105. MERCK & CO: KEY EXECUTIVES
TABLE 106. MERCK & CO: COMPANY SNAPSHOT
TABLE 107. MERCK & CO: PRODUCT SEGMENTS
TABLE 108. MERCK & CO: PRODUCT PORTFOLIO
TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES
TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT
TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS
TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO
TABLE 113. NOVARTIS AG: KEY EXECUTIVES
TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 117. PFIZER INC.: KEY EXECUTIVES
TABLE 118. PFIZER INC.: COMPANY SNAPSHOT
TABLE 119. PFIZER INC.: PRODUCT SEGMENTS
TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES
TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 125. SANOFI: KEY EXECUTIVES
TABLE 126. SANOFI: COMPANY SNAPSHOT
TABLE 127. SANOFI: PRODUCT SEGMENTS
TABLE 128. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. DIABETIC NEPHROPATHY MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF DIABETIC NEPHROPATHY MARKET,2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC NEPHROPATHY MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY 2021 AND 2031(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY COUNTRY 2021 AND 2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY COUNTRY 2021 AND 2031(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 17. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY COUNTRY 2021 AND 2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY COUNTRY 2021 AND 2031(%)
FIGURE 20. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021 AND 2031(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2021 AND 2031(%)
FIGURE 24. DIABETIC NEPHROPATHY MARKET BY REGION, 2021(%)
FIGURE 25. U.S. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 26. CANADA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 27. MEXICO DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 28. GERMANY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 29. FRANCE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 30. U.K. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 31. ITALY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 32. SPAIN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 33. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 34. JAPAN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 35. CHINA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 36. AUSTRALIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 37. INDIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 38. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 40. BRAZIL DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 41. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 42. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 43. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)
FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 48. COMPETITIVE DASHBOARD
FIGURE 49. COMPETITIVE HEATMAP: DIABETIC NEPHROPATHY MARKET
FIGURE 50. TOP PLAYER POSITIONING, 2021
FIGURE 51. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 53. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. REATA PHARMACEUTICALS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 67. REATA PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION)

Product Code: A16604

According to a new report published by Allied Market Research, titled, "Diabetic nephropathy Market," The diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.The diabetic nephropathy market is expected to reach $3,338.50 million by 2031. Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.

Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.

Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8-17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.

For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.

Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.

Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Product Benchmarking / Product specification and applications
Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
SWOT Analysis

Key Market Segments

By Distribution Channel

Hospital Pharmacy
Online Providers
Drug Stores and Retail Pharmacy

By Drugs Class

Angiotensin-converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Calcium Channel Blocker
Diuretics
Renin Inhibitor
Others

By Type

Type-1 Diabetes
Type-2 Diabetes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bayer AG
Abbott Laboratories
Astrazenica Plc
Eli Lilly and Company
Pfizer Inc.
Sanofi
Novartis AG
Merck & Co
AbbVie Inc.
Reata Pharmaceuticals

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension
  - 3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests

3.4.2. Restraints
- 3.4.2.1. Strict regulatory rules and lengthy drug approval times

3.4.3. Opportunities
- 3.4.3.1. Rise in use of combination therapy for diabetic nephropathy
- 3.4.3.2. Increase in R&D investments in drug discovery and development

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Angiotensin-converting Enzyme Inhibitors
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Angiotensin Receptor Blockers
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Calcium Channel Blocker
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Diuretics
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Renin Inhibitor
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
4.7. Others
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country

CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Type-1 Diabetes
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Type-2 Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacy
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacy
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drugs Class
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drugs Class
  - 7.2.5.1.3. Market size and forecast, by Type
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drugs Class
  - 7.2.5.2.3. Market size and forecast, by Type
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drugs Class
  - 7.2.5.3.3. Market size and forecast, by Type
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drugs Class
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drugs Class
  - 7.3.5.1.3. Market size and forecast, by Type
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drugs Class
  - 7.3.5.2.3. Market size and forecast, by Type
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. U.K.
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drugs Class
  - 7.3.5.3.3. Market size and forecast, by Type
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drugs Class
  - 7.3.5.4.3. Market size and forecast, by Type
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drugs Class
  - 7.3.5.5.3. Market size and forecast, by Type
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drugs Class
  - 7.3.5.6.3. Market size and forecast, by Type
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drugs Class
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drugs Class
  - 7.4.5.1.3. Market size and forecast, by Type
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drugs Class
  - 7.4.5.2.3. Market size and forecast, by Type
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drugs Class
  - 7.4.5.3.3. Market size and forecast, by Type
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drugs Class
  - 7.4.5.4.3. Market size and forecast, by Type
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drugs Class
  - 7.4.5.5.3. Market size and forecast, by Type
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drugs Class
  - 7.4.5.6.3. Market size and forecast, by Type
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drugs Class
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drugs Class
  - 7.5.5.1.3. Market size and forecast, by Type
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drugs Class
  - 7.5.5.2.3. Market size and forecast, by Type
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drugs Class
  - 7.5.5.3.3. Market size and forecast, by Type
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drugs Class
  - 7.5.5.4.3. Market size and forecast, by Type
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. AbbVie Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Abbott Laboratories
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Eli Lilly and Company
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Merck & Co
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Astrazenica Plc
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Novartis AG
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Pfizer Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Reata Pharmaceuticals
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Sanofi
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio

糖尿病性腎症市場：薬剤クラス別、タイプ別、流通チャネル別：世界の機会分析と産業予測、2022～2031年

Diabetic nephropathy Market By Drugs Class, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章糖尿病性腎症市場：薬剤クラス別

第5章糖尿病性腎症市場：タイプ別

第6章糖尿病性腎症市場：流通チャネル別

第7章糖尿病性腎症市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Distribution Channel

By Drugs Class

By Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

糖尿病性腎症市場：薬剤クラス別、タイプ別、流通チャネル別：世界の機会分析と産業予測、2022～2031年

Diabetic nephropathy Market By Drugs Class, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 糖尿病性腎症市場：薬剤クラス別

第5章 糖尿病性腎症市場：タイプ別

第6章 糖尿病性腎症市場：流通チャネル別

第7章 糖尿病性腎症市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Distribution Channel

By Drugs Class

By Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS

CHAPTER 5: DIABETIC NEPHROPATHY MARKET, BY TYPE

CHAPTER 6: DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: DIABETIC NEPHROPATHY MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章糖尿病性腎症市場：薬剤クラス別

第5章糖尿病性腎症市場：タイプ別

第6章糖尿病性腎症市場：流通チャネル別

第7章糖尿病性腎症市場：地域別

第8章競争情勢

第9章企業プロファイル